Literature DB >> 3566825

Acute transverse myelopathy successfully treated with plasmapheresis and prednisone in a patient with primary Sjögren's syndrome.

Y T Konttinen, E Kinnunen, M von Bonsdorff, P Lillqvist, I Immonen, V Bergroth, M Segerberg-Konttinen, C Friman.   

Abstract

We report a case of acute transverse myelopathy in a patient with primary Sjögren's syndrome of 3 years duration. Our patient's acute transverse myelopathy developed within 1 week and resulted in complete paraparesis below the mamillary level. Extensive laboratory investigation ruled out viral, bacterial, and fungal etiology, Guillain-Barré syndrome, poliomyelitis, and multiple sclerosis. At diagnosis, treatment was initiated immediately with prednisone (80 mg/day) and plasmapheresis, which was performed as a first-aid measure. Improvement was noted as early as 10 days after the start of therapy. Within 5 1/2 months of the first symptoms of paralysis, the patient walked without difficulty and returned to her normal activities. A causal relationship between plasmapheresis/prednisone therapy and recovery has not been proven but merits further consideration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3566825     DOI: 10.1002/art.1780300314

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

Review 1.  CNS involvement in primary Sjögren's syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach.

Authors:  M Govoni; M Padovan; N Rizzo; F Trotta
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  Rational drug therapy recommendations for the treatment of patients with Sjögren's syndrome.

Authors:  P Oxholm; J U Prause; M Schiødt
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 3.  Inflammatory Manifestations of Systemic Diseases in the Central Nervous System.

Authors:  David A Lapides; Mark M McDonald
Journal:  Curr Treat Options Neurol       Date:  2020-07-29       Impact factor: 3.598

4.  A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.

Authors:  Claudia F Lucchinetti; Raul N Mandler; Dorian McGavern; Wolfgang Bruck; Gerald Gleich; Richard M Ransohoff; Corinna Trebst; Brian Weinshenker; Dean Wingerchuk; Joseph E Parisi; Hans Lassmann
Journal:  Brain       Date:  2002-07       Impact factor: 13.501

Review 5.  Myelopathy in Sjögren's syndrome: role of nonsteroidal immunosuppressants.

Authors:  Susan J Rogers; Christopher S Williams; Gustavo C Román
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  A clinically isolated syndrome: a challenging entity: multiple sclerosis or collagen tissue disorders: clues for differentiation.

Authors:  Asli Kurne; Ilksen Colpak Isikay; Kader Karlioguz; Umut Kalyoncu; Omer Faruk Aydin; Meral Calguneri; Rana Karabudak
Journal:  J Neurol       Date:  2009-01-21       Impact factor: 4.849

7.  Neurological Disorders in Primary Sjögren's Syndrome.

Authors:  Gabriel J Tobón; Jacques-Olivier Pers; Valérie Devauchelle-Pensec; Pierre Youinou
Journal:  Autoimmune Dis       Date:  2012-03-05

8.  Refractory Sjögren's syndrome myelopathy successfully treated with subcutaneous tocilizumab: A case report.

Authors:  Yuichi Ishikawa; Koto Hattori; Junichi Ishikawa; Michio Fujiwara; Yasuhiko Kita
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

Review 9.  Transverse myelitis.

Authors:  Shin C Beh; Benjamin M Greenberg; Teresa Frohman; Elliot M Frohman
Journal:  Neurol Clin       Date:  2013-02       Impact factor: 3.806

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.